Synthomer Yönetim
Yönetim kriter kontrolleri 2/4
Synthomer CEO'su Michael Willome, Nov2021 tarihinde atandı, in görev süresi 4.83 yıldır. in toplam yıllık tazminatı £ 1.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.2% maaş ve 37.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.19% ine doğrudan sahiptir ve bu hisseler £ 320.11K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 2 yıldır.
Anahtar bilgiler
Michael Willome
İcra Kurulu Başkanı
UK£1.2m
Toplam tazminat
| CEO maaş yüzdesi | 62.22% |
| CEO görev süresi | 4.8yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 2yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Aug 17
SYNT: Higher Profitability Assumptions And Execution On Plans Will Support Future Upside
Analysts have trimmed their fair value estimate for Synthomer from £1.47 to £1.28, even as recent price target increases on the stock point to updated views on revenue growth, profitability and future P/E assumptions. Analyst Commentary Recent research on Synthomer gives investors a mixed message.Analiz Makalesi • Aug 08
Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results
Shareholders will be ecstatic, with their stake up 39% over the past week following Synthomer plc 's ( LON:SYNT...
Anlatı Güncellemesi • Aug 03
SYNT: Higher Fair Value And Execution Risks Will Shape Future Earnings
Analysts have raised their price target on Synthomer to £0.92 from £0.62, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key factors supporting the new level. Analyst Commentary Recent research updates on Synthomer suggest that, while targets have been adjusted, many analysts remain cautious about the stock.
Anlatı Güncellemesi • Jul 20
SYNT: Recent Price Objective Revisions Will Shape A More Constructive Outlook
The Analyst Price Target on Synthomer has been adjusted from £3.48 to £2.00 per share, reflecting analysts' updated assumptions on fair value, discount rate, and earnings profile in light of recent price target increases from £0.62 to £0.92 and an additional £0.40 uplift cited in Street research. Analyst Commentary Recent Street research on Synthomer points to a more constructive tone, with bullish analysts revisiting their fair value assumptions and revising price targets.Anlatı Güncellemesi • Jul 06
SYNT: Cost Actions And Execution On Plans Will Support Future Upside
Analysts have lifted their fair value estimate for Synthomer from £1.27 to £1.47, reflecting higher price targets from the Street and updated assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street commentary on Synthomer points to a more constructive stance on the stock, with price targets moving higher and ratings generally sitting in the neutral range.Anlatı Güncellemesi • Jun 22
SYNT: Leadership Change And Higher Risk Profile Will Pressure Future Earnings
Analysts have lifted their price target on Synthomer by £0.40, citing updated assumptions around discount rates, revenue growth and future P/E that they view as better aligned with the company’s current risk and earnings profile. What’s in the News for Synthomer Synthomer announced that Chief Financial Officer Lily Liu plans to step down to become Executive Vice President and Chief Financial Officer at Umicore SA.Anlatı Güncellemesi • Jun 06
SYNT: Leadership Transition Will Intensify Concerns Over Future Margin Stability
Analysts have nudged Synthomer's fair value higher, lifting the implied price target from £0.59 to £0.62. This reflects refreshed assumptions on revenue growth, discount rate and future P/E.Anlatı Güncellemesi • May 04
SYNT: Bio-Based Shift Will Face Margin And Leadership Risks Ahead
Analysts have kept their Synthomer fair value target steady at £0.59. This reflects a view that a shift from a previous revenue contraction of 32.37% to expected growth of 2.61%, together with a slightly lower projected profit margin of 9.99%, leaves the overall valuation framework broadly unchanged.Anlatı Güncellemesi • Apr 20
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.Anlatı Güncellemesi • Apr 06
SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).Anlatı Güncellemesi • Mar 23
SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.Anlatı Güncellemesi • Mar 09
SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).Anlatı Güncellemesi • Feb 22
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.Anlatı Güncellemesi • Feb 08
SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).Anlatı Güncellemesi • Jan 24
SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.Anlatı Güncellemesi • Jan 10
SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.Anlatı Güncellemesi • Dec 24
SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.Anlatı Güncellemesi • Dec 10
SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.Anlatı Güncellemesi • Nov 26
SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.Anlatı Güncellemesi • Nov 07
SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Anlatı Güncellemesi • Oct 24
Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.Analiz Makalesi • Aug 09
UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
There's been a major selloff in Synthomer plc ( LON:SYNT ) shares in the week since it released its half-year report...Anlatı Güncellemesi • Aug 07
Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.
Yeni Anlatı • Mar 31
Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Analiz Makalesi • Jan 08
Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Synthomer plc's ( LON:SYNT ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Analiz Makalesi • Oct 05
Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
You may think that with a price-to-sales (or "P/S") ratio of 0.2x Synthomer plc ( LON:SYNT ) is a stock worth checking...Analiz Makalesi • Aug 03
Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£2.63 With UK£2.46 share...Analiz Makalesi • Jun 18
Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • May 25
Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
Synthomer plc ( LON:SYNT ) shares have continued their recent momentum with a 27% gain in the last month alone. Still...Analiz Makalesi • Apr 20
Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£1.84 Current share price...Analiz Makalesi • Mar 14
Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Synthomer plc ( LON:SYNT ) shareholders would be excited to see that the share price has had a great month, posting a...Analiz Makalesi • Feb 08
Should You Think About Buying Synthomer plc (LON:SYNT) Now?
While Synthomer plc ( LON:SYNT ) might not have the largest market cap around , it saw a double-digit share price rise...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -UK£128m |
| Mar 31 2026 | n/a | n/a | -UK£139m |
| Dec 31 2025 | UK£1m | UK£723k | -UK£150m |
| Sep 30 2025 | n/a | n/a | -UK£107m |
| Jun 30 2025 | n/a | n/a | -UK£71m |
| Mar 31 2025 | n/a | n/a | -UK£72m |
| Dec 31 2024 | UK£2m | UK£702k | -UK£72m |
| Sep 30 2024 | n/a | n/a | -UK£79m |
| Jun 30 2024 | n/a | n/a | -UK£86m |
| Mar 31 2024 | n/a | n/a | -UK£96m |
| Dec 31 2023 | UK£1m | UK£675k | -UK£105m |
| Sep 30 2023 | n/a | n/a | -UK£127m |
| Jun 30 2023 | n/a | n/a | -UK£149m |
| Mar 31 2023 | n/a | n/a | -UK£84m |
| Dec 31 2022 | UK£987k | UK£650k | -UK£18m |
| Jun 30 2022 | n/a | n/a | UK£80m |
| Mar 31 2022 | n/a | n/a | UK£139m |
| Dec 31 2021 | UK£789k | UK£108k | UK£198m |
Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 1.56M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 808.56K ).
Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Michael Willome (60 yo)
4.8yrs
Görev süresi
UK£1,161,574
Tazminat
Mr. Michael Willome, lic. oec. HSG serves as the Chief Executive Officer at Synthomer plc since November 1, 2021 and serves as its Executive Director since November 2021.He had been Group Chief Executive...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | UK£1.16m | 0.19% £ 320.1k | |
| CFO & Executive Director | less than a year | Veri yok | Veri yok | |
| Vice President of Investor Relations | 3.7yrs | Veri yok | Veri yok | |
| General Counsel & Company Secretary | 3.8yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | less than a year | Veri yok | Veri yok | |
| President of Health | 8yrs | Veri yok | Veri yok | |
| President of Coatings & Construction Solutions and EMEA | 4.6yrs | Veri yok | Veri yok | |
| President of Strategy and M&A | 4yrs | Veri yok | Veri yok | |
| President of Adhesive Solutions and Americas | 3.3yrs | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: SYNT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | UK£1.16m | 0.19% £ 320.1k | |
| CFO & Executive Director | less than a year | Veri yok | Veri yok | |
| Non-Executive Director | 24yrs | UK£48.00k | 0.10% £ 165.2k | |
| Independent Non-Executive Director | 1.2yrs | UK£32.08k | 0.036% £ 59.8k | |
| Independent Non-Executive Chairman | 2yrs | UK£251.32k | 0.030% £ 50.5k | |
| Independent Non-Executive Director | 3yrs | UK£63.00k | Veri yok | |
| Independent Non-Executive Director | 8yrs | UK£73.00k | 0.015% £ 24.2k | |
| Non-Executive Director | 2yrs | UK£48.00k | 0.030% £ 50.5k | |
| Senior Independent Director | 1.2yrs | UK£32.01k | 0.012% £ 20.1k |
2.0yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SYNT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/17 18:22 |
| Gün Sonu Hisse Fiyatı | 2026/09/17 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Synthomer plc 14 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Sebastian Bray | Berenberg |
| Rikin Patel | BNP Paribas |
| Kevin Fogarty | Deutsche Bank |